Interestingly, copanlisib is being studied in advanced HER2+ BC in addition to pertuzumab and trastuzumab to evaluate if this combination can overcome the resistance caused by the hyperactivation of the PI3K pathway [68]. This evidence concerns the gene ERBB2 and breast cancer.